VGLS — VG Life Sciences Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $2.11m
- $6.11m
Annual income statement for VG Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2010 December 31st | 2011 December 31st | R2012 December 31st | 2013 December 31st | 2014 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PRESS | PRESS | 10-Q | 10-Q | 10-K |
Standards: | — | — | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.006 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2.67 | 4.07 | 2.6 | 3.91 | 4.14 |
Operating Profit | -2.66 | -4.07 | -2.6 | -3.91 | -4.14 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.24 | -5.49 | -6.94 | -7.48 | -6.22 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.24 | -5.49 | -6.94 | -7.48 | -6.22 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7.24 | -5.42 | -6.85 | -7.42 | -6.19 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -7.24 | -5.42 | -6.85 | -7.42 | -6.19 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.85 | -4.42 | -3.19 | -0.906 | -0.224 |
Dividends per Share |